Previous 10 | Next 10 |
Common Stock Will Begin Trading on a Split-Adjusted Basis on January 24, 2024 Inseego Corp. (Nasdaq: INSG) (the “Company”) today announced that it intends to effect a 1-for-10 reverse stock split of its issued and outstanding shares of common stock (the “Reverse Sto...
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader PR Newswire Fireside Chat, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, January 24, 2024, ...
2024-01-19 19:39:39 ET Summary FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients wi...
2024-01-17 17:51:36 ET Summary CHRS has a pipeline of biosimilars including Yusimry, Cimerli, and Udenyca. A new form of Udenyca, Udenyca Onbody, was approved in December 2023. CHRS also has a new drug Loqtorzi (toripalimab) which was approved in the US for the treatment of nasoph...
2024-01-05 14:00:38 ET More on Inovio Pharmaceuticals Inovio Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Inovio Pharmaceuticals, Inc. (INO) Q3 2023 Earnings Call Transcript Inovio plans to submit BLA to FDA for INO-3107 in 2H Bank of ...
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) PR Newswire - Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanc...
2024-01-03 08:52:36 ET More on Inovio Pharmaceuticals Inovio Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Inovio Pharmaceuticals, Inc. (INO) Q3 2023 Earnings Call Transcript Bank of America more favorable on SMID-cap biotechs into 2024 ...
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program PR Newswire Company will request Rolling Submission and Priority Review of its Biological License Application (BLA) by U.S. Food and Drug Admi...
2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...
Experienced Channel Sales Executive Keri Bolding joins Inseego Inseego Corp. (Nasdaq: INSG), a leader in 5G edge cloud solutions, today announced Keri Bolding has joined the company in the newly-created role of SVP of Global Channel Sales & Distribution. Bolding will oversee the com...
News, Short Squeeze, Breakout and More Instantly...
Inovio Pharmaceuticals Inc. Company Name:
INO Stock Symbol:
NASDAQ Market:
Inovio Pharmaceuticals Inc. Website:
2024-07-16 13:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Inseego Corp. (Nasdaq: INSG), a technology leader in 5G mobile and fixed wireless solutions for mobile network operators, Fortune 500 enterprises and SMBs, today announced that the company will release its financial results for the second quarter of 2024, ended June 30, 2024, after the financial ...
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway PR Newswire Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respi...